Single amino acid (482) variants of the ABCG2 multidrug transporter: Major differences in transport capacity and substrate recognition

Biochimica et Biophysica Acta - Biomembranes

Volumn 1668, Issue 1, 2005, Pages 53-63

  Özvegy Laczka, Csilla ^a,b   Köblös, Gabriella ^b   Sarkadi, Balázs ^a   Váradi, András ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b INSTITUTE OF ENZYMOLOGY   (Hungary)

Author keywords

Cell surface localization; Fluorescent dye extrusion; Membrane ATPase; Multidrug half transporter; Single amino acid mutant; Vesicular transport

Indexed keywords

ABC TRANSPORTER; ABCG2 MULTIDRUG TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ARGININE DERIVATIVE; GLYCOPROTEIN P; HOE 33342; METHOTREXATE; MITOXANTRONE; RHODAMINE 123; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; INSECT CELL; MEMBRANE VESICLE; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; TRANSPORT KINETICS; WILD TYPE;

ADENOSINE TRIPHOSPHATASES; AMINO ACID SUBSTITUTION; ANIMALS; ARGININE; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; METHOTREXATE; MUTATION; NEOPLASM PROTEINS; RHODAMINE 123; SPODOPTERA; SUBSTRATE SPECIFICITY;

INSECTA;

EID: 12844255054     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2004.11.005     Document Type: Article

References (40)

1. J.D. Allen, and A.H. Schinkel Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2) Mol. Cancer Ther. 1 2002 427 434
2. S.E. Bates, R. Robey, K. Miyake, K. Rao, D.D. Ross, and T. Litman The role of half-transporters in multidrug resistance J. Bioenerg. Biomembranes 33 2001 503 511
3. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, A.H. Schinkel, M.J. van De Vijver, R.J. Scheper, and J.H. Schellens Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues Cancer Res. 61 2001 3458 3464
4. S. Zhou, J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris, I. Lagutina, G.C. Grosveld, M. Osawa, H. Nakauchi, and B.P. Sorrentino The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype Nat. Med. 7 2001 1028 1034
5. T. Litman, T.E. Druley, W.D. Stein, and S.E. Bates From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell. Mol. Life Sci. 58 2001 931 959
6. E.L. Volk, K.M. Farley, Y. Wu, F. Li, R.W. Robey, and E. Schneider Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance Cancer Res. 62 2002 5035 5040
7. J.W. Jonker, M. Buitelaar, E. Wagenaar, M.A. Van Der Valk, G.L. Scheffer, R.J. Scheper, T. Plosch, F. Kuipers, R.P. Elferink, H. Rosing, J.H. Beijnen, and A.H. Schinkel The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria Proc. Natl. Acad. Sci. U. S. A. 99 2002 15649 15654
8. A.E. van Herwaarden, J.W. Jonker, E. Wagenaar, R.F. Brinkhuis, J.H. Schellens, J.H. Beijnen, and A.H. Schinkel The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine Cancer Res. 63 2003 6447 6452
9. G.L. Scheffer, M. Maliepaard, A.C. Pijnenborg, M.A. van Gastelen, M.C. de Jong, A.B. Schroeijers, D.M. van der Kolk, J.D. Allen, D.D. Ross, P. van der Valk, W.S. Dalton, J.H. Schellens, and R.J. Scheper Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines Cancer Res. 60 2000 2589 2593
10. J.W. Jonker, J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, J.H. Schellens, and A.H. Schinkel Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J. Natl. Cancer Inst. 92 2000 1651 1656
11. C.M. Kruijtzer, J.H. Beijnen, H. Rosing, W.W. ten Bokkel Huinink, M. Schot, R.C. Jewell, E.M. Paul, and J.H. Schellens Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J. Clin. Oncol. 20 2002 2943 2950
12. T.W. Loo, and D.M. Clarke The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface J. Biol. Chem. 274 1999 24759 24765
13. P. Hafkemeyer, S. Dey, S.V. Ambudkar, C.A. Hrycyna, I. Pastan, and M.M. Gottesman Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein Biochemistry (Mosc.) 37 1998 16400 16409
14. K. Ueda, Y. Taguchi, and M. Morishima How does P-glycoprotein recognize its substrates? Semin. Cancer Biol. 8 1997 151 159
15. Y. Taguchi, K. Kino, M. Morishima, T. Komano, S.E. Kane, and K. Ueda Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein Biochemistry (Mosc.) 36 1997 8883 8889
16. K.H. Choi, C.J. Chen, M. Kriegler, and I.B. Roninson An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene Cell 53 1988 519 529
17. M. Ramachandra, S.V. Ambudkar, M.M. Gottesman, I. Pastan, and C.A. Hrycyna Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system Mol. Biol. Cell 7 1996 1485 1498
18. C.O. Cardarelli, I. Aksentijevich, I. Pastan, and M.M. Gottesman Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters Cancer Res. 55 1995 1086 1091
19. D.W. Zhang, H.M. Gu, D. Situ, A. Haimeur, S.P. Cole, and R.G. Deeley Functional importance of polar and charged amino acid residues in transmembrane helix 14 of multidrug resistance protein 1 (MRP1/ABCC1): identification of an aspartate residue critical for conversion from a high to low affinity substrate binding state J. Biol. Chem. 278 2003 46052 46063
20. D.W. Zhang, H.M. Gu, M. Vasa, M. Muredda, S.P. Cole, and R.G. Deeley Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3 Biochemistry (Mosc.) 42 2003 9989 10000
21. K. Koike, C.J. Oleschuk, A. Haimeur, S.L. Olsen, R.G. Deeley, and S.P. Cole Multiple membrane-associated tryptophan residues contribute to the transport activity and substrate specificity of the human multidrug resistance protein, MRP1 J. Biol. Chem. 277 2002 49495 49503
22. Y. Honjo, C.A. Hrycyna, Q.W. Yan, W.Y. Medina-Perez, R.W. Robey, A. van de Laar, T. Litman, M. Dean, and S.E. Bates Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res. 61 2001 6635 6639
23. J.D. Allen, S.C. Jackson, and A.H. Schinkel A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance Cancer Res. 62 2002 2294 2299
24. X. Wang, T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto, S. Akiyama, and M. Baba Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors Mol. Pharmacol. 63 2003 65 72
25. C. Özvegy, A. Váradi, and B. Sarkadi Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation J. Biol. Chem. 277 2002 47980 47990
26. Z.S. Chen, R.W. Robey, M.G. Belinsky, I. Shchaveleva, X.Q. Ren, Y. Sugimoto, D.D. Ross, S.E. Bates, and G.D. Kruh Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-d-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport Cancer Res. 63 2003 4048 4054
27. M. Miwa, S. Tsukahara, E. Ishikawa, S. Asada, Y. Imai, and Y. Sugimoto Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants Int. J. Cancer 107 2003 757 763
28. G. Szakács, C. Özvegy, É. Bakos, B. Sarkadi, and A. Váradi Role of glycine-534 and glycine-1179 of human multidrug resistance protein (MDR1) in drug-mediated control of ATP hydrolysis Biochem. J. 356 2001 71 75
29. M. Müller, É. Bakos, E. Welker, A. Váradi, U.A. Germann, M.M. Gottesman, B.S. Morse, I.B. Roninson, and B. Sarkadi Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein J. Biol. Chem. 271 1996 1877 1883
30. B. Sarkadi, E.M. Price, R.C. Boucher, U.A. Germann, and G.A. Scarborough Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase J. Biol. Chem. 267 1992 4854 4858
31. É. Bakos, R. Evers, G. Szakács, G.E. Tusnády, E. Welker, K. Szabó, M. de Haas, L. van Deemter, P. Borst, A. Váradi, and B. Sarkadi Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain J. Biol. Chem. 273 1998 32167 32175
32. C. Özvegy, T. Litman, G. Szakács, Z. Nagy, S. Bates, A. Váradi, and B. Sarkadi Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells Biochem. Biophys. Res. Commun. 285 2001 111 117
33. J.D. Allen, A. van Loevezijn, J.M. Lakhai, M. van der Valk, O. van Tellingen, G. Reid, J.H. Schellens, G.J. Koomen, and A.H. Schinkel Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C Mol. Cancer Ther. 1 2002 417 425
34. R.W. Robey, Y. Honjo, K. Morisaki, T.A. Nadjem, S. Runge, M. Risbood, M.S. Poruchynsky, and S.E. Bates Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br. J. Cancer 89 2003 1971 1978
35. E.L. Volk, and E. Schneider Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter Cancer Res. 63 2003 5538 5543
36. G.M. Denning, M.P. Anderson, J.F. Amara, J. Marshall, A.E. Smith, and M.J. Welsh Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive Nature 358 1992 761 764
37. A. Bodó, É. Bakos, F. Szeri, A. Váradi, and B. Sarkadi Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions J. Biol. Chem. 278 2003 23529 23537
38. D.R. Stenham, J.D. Campbell, M.S. Sansom, C.F. Higgins, I.D. Kerr, and K.J. Linton An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling FASEB J. 17 2003 2287 2289
39. J.D. Campbell, K. Koike, C. Moreau, M.S. Sansom, R.G. Deeley, and S.P. Cole Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1) J. Biol. Chem. 279 2004 463 468
40. O. Ujhelly, C. Özvegy, G. Várady, J. Cervenak, L. Homolya, M. Grez, G. Scheffer, D. Roos, S.E. Bates, A. Váradi, B. Sarkadi, and K. Német Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells Hum. Gene Ther. 14 2003 403 412